

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

1



of


1

Complete if Known

Application Number	Unassigned
Filing Date	Herewith
First Named Inventor	Wang et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	015280-367200US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	REN, M. et al., "Effects of mutant ran/TC proteins on cell cycle progression," Molecular and Cellular Biology, June 1994, pp. 4216-4224, Vol. 14(6).	
	AB	RICHARDS, S.A. et al., "The C terminus of the nuclear RAN/TC4 GTPase stabilizes the GDP-bound state and mediates interactions with RCC, RAN-GAP and HTF9A/RANBP1," Journal of Biological Chemistry, 1995, pp. 14405-14411, Vol. 270(24).	
	AC	SMITH, M.L. et al., "Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation of cisplatin," Oncogene, 1996, pp. 2255-2263, Vol. 13.	
	AD	TAKEKAWA, M. and SAITO, H., "A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK, Cell, November 13, 1998, pp. 521-530, Vol. 95.	
	AE	YANG, Q. et al., "Mechanisms of a GADD45-mediated G2/M checkpoint," AACR special conference, Genetic and Functional Consequences of Cell Cycle Alteration in Cancer, October 20-24, 1999, San Diego, California, USA.	
	AF	ZHAN, Q. et al., "Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45," Oncogene, 1999, pp. 2892-2900, Vol. 18.	
	AG	ZHAN, Q. et al., "Tumor suppressor p53 can participate in transcriptional induction of the GADD45 promoter in the absence of direct DNA binding," Molecular and Cellular Biology, May 1998, pp. 2768-2778, Vol. 18(5).	

Examiner
Signature

Date

Considered

5-15-04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.